Cargando…

Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma

Glypican-3 (GPC3) has become a compelling target for immunotherapy of hepatocellular carcinoma, including antibody-drug conjugate (ADC), and ADC-like immunotoxin. To investigate the impact of epitopes on the potency of ADCs, current study generated a large panel of chicken monoclonal antibodies (mAb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jingwen, Xiang, Lanxin, Wang, Qian, Ma, Xuqian, Chen, Xin, Zhu, Yuankui, Yang, Yaxi, Huang, Le, He, Huixia, Xu, Lilei, Liang, Xinjun, Dong, Shuang, Hu, Sheng, Li, Hanjie, Feng, Mingqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899386/ https://www.ncbi.nlm.nih.gov/pubmed/35281879 http://dx.doi.org/10.7150/jca.66978

Ejemplares similares

Recombinant immunotoxin targeting GPC3 is cytotoxic to H446 small cell lung cancer cells
por: Rodakowska, Ewelina, et al.
Publicado: (2021)

Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells
por: Yang, Liu, et al.
Publicado: (2021)

Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect
por: Heiat, Mohammad, et al.
Publicado: (2021)

Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments
por: Li, Weiyue, et al.
Publicado: (2018)

Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
por: Eisen, Tim, et al.
Publicado: (2014)

Novel Chemokine-Based Immunotoxins for Potent and Selective Targeting of Cytomegalovirus Infected Cells
por: Spiess, Katja, et al.
Publicado: (2017)

GPC-3 in hepatocellular carcinoma: current perspectives
por: Wu, Yongle, et al.
Publicado: (2016)

Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma
por: Zheng, Youshi, et al.
Publicado: (2023)

Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
por: Wang, Chunguang, et al.
Publicado: (2016)

Low glucose metabolism in hepatocellular carcinoma with GPC3 expression
por: Li, You-Cai, et al.
Publicado: (2018)

Immunotoxins: experimental design
por: Dall, P, et al.
Publicado: (2001)

Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013)

Countering immunotoxin immunogenicity
por: Flavell, David J
Publicado: (2016)

Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)

The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy
por: Xiang, Xinran, et al.
Publicado: (2011)

Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signaling and protein synthesis
por: Gao, Wei, et al.
Publicado: (2015)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Novel EGFR-bispecific recombinant immunotoxin based on cucurmosin shows potent anti-tumor efficiency in vitro
por: Zhang, Caiyun, et al.
Publicado: (2021)

Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2014)

ENGINEERING T CELLS TARGETING GPC2 FOR TREATING NEUROBLASTOMA
por: Quan, Alex, et al.
Publicado: (2023)

Treatment of solid tumors with immunotoxins
por: Messmer, Davorka, et al.
Publicado: (2005)

Bouganin, an Attractive Weapon for Immunotoxins
por: Bortolotti, Massimo, et al.
Publicado: (2018)

Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager
por: Bi, Yanyu, et al.
Publicado: (2017)

Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells
por: Tang, Jinle, et al.
Publicado: (2016)

Development of anti-GPC-1 (glypican-1)-CAR-T cells for adoptive T cell immunotherapies for squamous cell carcinoma
por: Yaguchi, Tomonori, et al.
Publicado: (2015)

Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis
por: Sun, Bin, et al.
Publicado: (2017)

Preparation and Characterization of Anti-GPC3 Nanobody Against Hepatocellular Carcinoma
por: Xia, Lijie, et al.
Publicado: (2020)

Clinical targeting recombinant immunotoxins for cancer therapy
por: Li, Meng, et al.
Publicado: (2017)

Cytotoxins and immunotoxins for cancer therapy : clinical applications /
Publicado: (2005)

Immunotoxins: From Design to Clinical Application
por: Kreitman, Robert J., et al.
Publicado: (2021)

Toxin and Immunotoxin Based Therapeutic Approaches
por: Bortolotti, Massimo, et al.
Publicado: (2022)

Elevated GPC3 level promotes cell proliferation in liver cancer
por: Wang, Shanshan, et al.
Publicado: (2018)

GPC6 Promotes Cell Proliferation, Migration, and Invasion in Nasopharyngeal Carcinoma
por: Fan, Chunmei, et al.
Publicado: (2019)

Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer
por: Park, Jun Young, et al.
Publicado: (2020)

Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC
por: Li, Dezhi, et al.
Publicado: (2023)

Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC
por: Wang, Yuliang, et al.
Publicado: (2011)

GPC1 Is Associated with Poor Prognosis and Treg Infiltration in Colon Adenocarcinoma
por: Liu, Ying, et al.
Publicado: (2022)

Association between GPC2 polymorphisms and neuroblastoma risk in Chinese children
por: Li, Meng, et al.
Publicado: (2023)

Systemic immunotoxin therapy of cancer: advances and prospects.
por: Wawrzynczak, E. J.
Publicado: (1991)

Efficiency of Immunotoxin Cytotoxicity Is Modulated by the Intracellular Itinerary
por: Tortorella, Lori L., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ndjaci76385qkaaa39etkq25n6